Oral GLP-1 vs. Injection: Wegovy Pill, Foundayo, and What Women Over 40 Should Know

For four years the GLP-1 conversation had one shape: a weekly injection, a pen in the fridge, and a price that put it out of reach for most women without insurance. That era ended quietly over the past nine months. There are now two GLP-1 pills approved for weight management in the United States, a third generation of molecules is posting results that make today's drugs look modest, and the pricing has shifted enough that women who dismissed this category are asking about it again.

I've written before about semaglutide and tirzepatide for women specifically. This is the update — what the pills change, what they don't, and the question a woman in her forties or fifties should be asking that a twenty-eight-year-old doesn't have to.

What's actually available now

Oral Wegovy (semaglutide 25 mg). Approved December 22, 2025, in pharmacies from January 2026. Same molecule as the injection, taken as a once-daily pill. In its phase 3 trial it produced roughly 16% average weight loss over about 64 weeks in adults who stayed on treatment — in the same range as the injection. The catch is how it has to be taken: first thing in the morning, on an empty stomach, with no more than a few ounces of water, and then a thirty-minute wait before anything else. That's because only a small fraction of oral semaglutide is absorbed, and food destroys even that.

Foundayo (orforglipron). Approved April 1, 2026. This one is different in kind — it's a small-molecule, non-peptide GLP-1 agonist, which means it doesn't need the absorption tricks. It can be taken any time of day, with or without food or water. In its main trial, the highest dose produced about 12.4% average weight loss versus under 1% on placebo — a step below oral Wegovy and well below injectable tirzepatide, but with a convenience profile nothing else in the class matches. It comes in six dose strengths, escalated gradually.

What's coming. CagriSema, a combination of semaglutide with an amylin analog, is under FDA review with a decision expected this year. Retatrutide, a triple agonist from Lilly, reported 28.3% weight loss in its first phase 3 trial — the strongest result the class has produced. Neither is a pill yet, but both are where the injectables are heading.

Pill or shot: how I'd think about it

If you're new to GLP-1s and the needle was the barrier, Foundayo is the easiest entry point ever offered in this class, and for a woman with fifteen to twenty-five pounds to lose, its numbers are enough. If you have more to lose or a strong insulin-resistance picture, oral Wegovy's higher efficacy is worth the morning ritual.

If you're already on injectable tirzepatide and it's working, I would not switch. Nothing oral matches it yet, and the dual-receptor mechanism has particular advantages for women in midlife that I covered in the tirzepatide piece. Switching for convenience usually costs you results.

If you're on injectable semaglutide and considering the pill, it's a reasonable lateral move — same drug, similar efficacy — provided the empty-stomach timing fits your life. If you take thyroid medication in the morning, this needs thought: both want an empty stomach and a wait, and stacking them requires a plan.

On cost: the pricing announced alongside the pill launches put the lowest doses at roughly $150 a month for self-pay, a fraction of what injections cost at launch. Prices change fast in this category, so treat that as a snapshot and check current cash-pay pricing directly.

The question that doesn't change with the formulation

Here is what the marketing for every one of these products leaves out. Somewhere between a quarter and forty percent of the weight lost on GLP-1 therapy is lean tissue, not fat — muscle, bone, connective tissue. In a thirty-year-old that's a problem. In a woman whose estrogen is already declining, whose muscle mass and bone density are already trending down every year, it's a different order of problem. You can lose thirty pounds and be metabolically worse off: lighter, weaker, more insulin-resistant per pound of muscle, with a skeleton that has lost ground it won't easily recover.

The pill doesn't change this. Neither does the injection. What changes it is what you do around the medication — and I've written a companion piece on protecting muscle on a GLP-1 because it deserves its own space. The short version: deliberate protein, progressive strength training, and body composition measured instead of scale weight, built in from the first dose rather than added when the loss of strength becomes obvious.

Before you start any of them

I still want the foundation assessed first. A full thyroid panel, fasting insulin, ferritin, vitamin D, and — for a woman in her forties or fifties — hormone levels, because a share of what brings women to GLP-1s is a thyroid or estrogen problem wearing a weight-loss costume. That doesn't disqualify the medication. It means the medication works better and the weight stays off when the system underneath it is working.

And the class-wide cautions apply to the pills exactly as they do to the injections: the thyroid C-cell tumor boxed warning, pancreatitis and gallbladder risk, and — the one women are least often told — reduced absorption of oral contraceptives during dose escalation, which I detailed in the tirzepatide article.

---

The pill era makes GLP-1s more accessible than they have ever been. It doesn't make them simpler. The women who do best on these medications in midlife are the ones who treat the prescription as one part of a plan for a body that is losing muscle and bone with or without the drug — and who choose the formulation second, after they've decided what they're protecting.

References

1. Novo Nordisk. “Wegovy pill marks first GLP-1 weight-loss medicine in oral form.” January 2026. View source
2. Consultant360. “FDA Approves Orforglipron (Foundayo) for Chronic Weight Management.” April 2026. View source
3. diaTribe. “New Oral Drug Foundayo for Weight Loss.” April 2026. View source
4. Drug Topics. “Results Show Bimagrumab With Semaglutide Achieve Substantial Weight Reduction” (BELIEVE, Nature Medicine), March 2026. View source

Oral semaglutide (Wegovy) and orforglipron (Foundayo) are FDA-approved for chronic weight management. CagriSema and retatrutide are investigational and not FDA-approved. Regulatory status was checked against FDA materials current at the time of publication.